SOLARA Solara Active Pharma Sciences Q4 FY26 results (Jan–Mar 2026) and concall
Solara Active Pharma Sciences reported a robust Q4 FY26, marking its best performance in eight quarters across key financial metrics, primarily driven by its high-margin base business. The company made significant strides in debt reduction and revitalized its R&D pipeline. However, the ibuprofen business remains a drag, with its strategic future still pending a decision in the coming quarters.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 41.8%, net profit up 600.0% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 300 | 273 | 319 | 314 | 349 +16% | 387 +42% |
| EBITDA | 58 | 45 | 57 | 35 | 37 −36% | 58 +29% |
| Net profit | 8 | -2 | 11 | -10 | -17 −312% | 10 +600% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
